Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Positron Emission Tomography01:29

Positron Emission Tomography

5.4K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
5.4K
Cancer Vaccines01:30

Cancer Vaccines

509
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
509
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Linking deubiquitination to pyroptosis: new perspectives from OTUB1 in hepatocellular carcinoma.

Journal of gastrointestinal oncology·2026
Same author

Molecular insights and therapeutic implications for the tumor suppressor role of LKB1 in non-small cell lung cancer.

Cancer letters·2026
Same author

Discovery of New OTUB1 Covalent Ligands via Structure-Activity Relationship Studies for Targeted Protein Stabilization.

Journal of medicinal chemistry·2026
Same author

Aberrant amino acid-sensing promotes immunotherapy resistance via the inflammatory cytokine-ZBTB5-mTORC1 axis.

Nature cell biology·2026
Same author

Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications.

Signal transduction and targeted therapy·2026
Same author

Endocytic Adaptor Proteins in Vascular Diseases: Critical Role of Intracellular Trafficking in Regulating Pathobiology of Vascular Disorders.

Cardiology discovery·2026

関連する実験動画

Updated: Sep 8, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.5K

前立腺がん治療のためのPROTAC技術

Zhen Wang1, Dingpeng Zhang1, Hiroyuki Inuzuka1

  • 1Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

Acta materia medica
|August 20, 2025
PubMed
まとめ

前立腺がん (PrCa) は男性に多く見られるがんである. このレビューは,PrCaバイオマーカーと新しいカストレーション耐性PrCa (CRPC) 治療をカバーし,耐性に対抗するプロテオリシス標的キメラ (PROTAC) を強調しています.

科学分野:

  • 腫瘍学
  • 泌尿器科
  • 分子生物学

背景:

  • 前立腺がん (PrCa) は,最も一般的な男性泌尿器がんであり,転移により死亡率が高い.
  • PrCaの進行の主な要因は,遺伝的変異,アンドロゲン受容体 (AR) 信号伝達,およびAR結合変異が含まれています.
  • アンドロゲン欠乏療法 (ADT) は初期PrCaの標準ですが,しばしばカストレーション抵抗性PrCa (CRPC) につながります.

研究 の 目的:

  • 前立腺がんの検出とモニタリングのための重要なバイオマーカーをレビューする.
  • カストレーション抵抗性前立腺がん (CRPC) の新たな治療戦略を探求する.
  • タンパク質分解を標的とするキメラ (PROTAC) 技術のCRPC耐性メカニズムを克服する可能性を強調する.

主な方法:

  • 前立腺がんの進行と治療抵抗に関する文献レビュー.
  • CRPCの現在の治療法と試験中の治療法の分析
  • 癌治療におけるPROTAC技術のメカニズムと応用

主要な成果:

  • PrCaの進行とADTに対する抵抗に寄与する主要な遺伝的および分子的要因を特定した.
  • CRPCの既定および新しい治療目標の概要

さらに関連する動画

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

8.0K

関連する実験動画

Last Updated: Sep 8, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.5K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

8.0K
  • 標的タンパク質の分解におけるPROTACのメカニズムとそのCRPCに対する潜在的な有効性について詳細に説明しました.

    • 結論:

    • 前立腺がんは 効果的なバイオマーカーと 治療戦略の継続的な研究を必要とします
    • CRPCは依然として重要な臨床課題であり,革新的な治療方法が必要です.
    • PROTAC技術は,CRPCの治療抵抗性を克服するための次世代の治療法の開発に有望な道を示しています.